Headlines about Ophthotech (NASDAQ:OPHT) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ophthotech earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.4595958582091 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Several equities analysts recently commented on the company. Chardan Capital reissued a “hold” rating and issued a $4.00 target price on shares of Ophthotech in a report on Wednesday, June 13th. ValuEngine lowered Ophthotech from a “hold” rating to a “sell” rating in a report on Monday, July 2nd. Finally, Zacks Investment Research raised Ophthotech from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a report on Monday, May 14th. Two analysts have rated the stock with a sell rating and three have assigned a hold rating to the company. Ophthotech has a consensus rating of “Hold” and a consensus target price of $3.67.
Shares of Ophthotech traded down $0.05, hitting $2.44, during mid-day trading on Friday, MarketBeat reports. 43,692 shares of the stock were exchanged, compared to its average volume of 138,246. The firm has a market cap of $90.13 million, a price-to-earnings ratio of 0.77 and a beta of 1.31. Ophthotech has a 12-month low of $2.25 and a 12-month high of $4.50.
Ophthotech (NASDAQ:OPHT) last issued its quarterly earnings data on Wednesday, August 1st. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.02. research analysts forecast that Ophthotech will post -1.57 EPS for the current fiscal year.
Ophthotech Company Profile
Ophthotech Corporation, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, for dry and wet forms of age-related macular degeneration, a disorder of the central portion of the retina known as the macula.
Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.